Key statistics dashboard for None (GDTC). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies.
Stock Data
| Price | $0.89 |
| Market Cap | $10M |
| Enterprise Value | $11.8M |
| Beta | -0.21 |
Valuation Multiples
| P/E Ratio | -2.72 |
| Price / Book | 1.98 |
| P/S | 20.24 |
| EV/EBITDA | -2.23 |
| EV/Sales | 18.33 |
| EV/FCF | -1.86 |
| P/FCF | -2.05 |
| Earnings Yield | -36.35% |
| FCF Yield | -47.32% |
Profitability
| Gross Margin | -20.48% |
| EBIT Margin | -884.73% |
| EBITDA Margin | -820.34% |
| Operating Margin | -672.18% |
| Net Margin | -754.66% |
| Return on Equity | -70.74% |
| Return on Assets | -60.74% |
| Return on Invested Capital | -58.88% |
| Return on Capital Employed | -59.37% |
Financial Health
| Current Ratio | 5.17 |
| Quick Ratio | 3.66 |
| Cash Ratio | 2.95 |
| Debt / Equity | 0.07 |
| Debt / Assets | 6.04% |
| Net Debt / EBITDA | 0.31 |
| Interest Coverage | -209.99 |
| Piotroski F-Score | 2 |
| Altman Z-Score | 5.96 |
Per-Share Data
| Revenue per share | 0.05 |
| Book Value per share | 0.58 |
| Cash per share | 0.18 |
| FCF per share | -0.54 |
| Tangible Book Value per share | 0.57 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 1 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 1 |
| Avg rating (1-5) | 1.00 |